 |
| ||||||||||||||
 |
||||||||||||||
|
|
 |
|
Thank you for your interest in OMML. We're happy to answer questions about our company, and you can also find additional information on our website by clicking on these topics: Please note that we cannot provide answers to personal medical questions. To obtain such answers you should contact your healthcare provider. Also note that this system is not designed to respond to product complaints. For questions/comments regarding ABILIFY® (aripiprazole) Tablets1, call (800) 321-1335 For questions/comments regarding PLETAL® (cilostazol) Tablets2, call Otsuka's Medical Affairs Department at (800) 441-6763 toll free For questions/comments regarding ZEGERID® (omeprazole/sodium bicarbonate)3 call (888) 778-0887 For information regarding Otsuka's Adacolumn clinical trials for ulcerative colitis or crohn's disease, call (866) 560-5828 or e-mail adacolumn@robarts.ca For information regarding Otsuka's Polycystic Kidney Disease clinical trials, call (866) 712-5837 We are not currently enrolling additional patients in Otsuka's Hyponatremia clinical trials, however, please continue to monitor www.clinicaltrials.gov for future information We are not currently enrolling additional patients in Otsuka's Dry Eye clinical trials, however, please continue to monitor www.clinicaltrials.gov for future information
Corporate Headquarters/General Inquiries
Career
Information/Resumes
Media
Contact/Public Relations (U.S.)
Questions About Otsuka Pharmaceutical Products (U.S. Residents Only)
Website Questions
2 Please see FULL PRODUCT INFORMATION including Boxed WARNINGS for PLETAL. 3 Please see FULL PRODUCT INFORMATION for ZEGERID. |
| * OAPI, OPDC, and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established by OPC in the U.S. in 1989 |